MétaCan
Menu
Back to cohort
Record W2646828059 · doi:10.1186/s13063-017-2026-0

Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial

2017· article· en· W2646828059 on OpenAlexafffund
Michael H. Livingston, Sanjay Mahant, Félix Ratjen, Bairbre Connolly, Kevin E. Thorpe, Muhammad Mamdani, Ian MacLusky, Sophie Laberge, Lucy Giglia, J. Mark Walton, Connie Yang, Ashley Roberts, Anna C. Shawyer, Mary Brindle, Simon Parsons, Cristina Stoian, Eyal Cohen

Bibliographic record

VenueTrials · 2017
Typearticle
Languageen
FieldMedicine
TopicPleural and Pulmonary Diseases
Canadian institutionsAlberta Children's HospitalUniversity of CalgaryBC Children's HospitalHospital for Sick ChildrenUniversité de MontréalChildren's Hospital of Eastern OntarioUniversity of OttawaSt. Michael's HospitalUniversity of TorontoSickKids FoundationUniversity of British ColumbiaCentre Hospitalier Universitaire Sainte-JustineMcMaster UniversityMcMaster Children's Hospital
FundersCanadian Institutes of Health ResearchPhysicians' Services Incorporated FoundationOntario Ministry of Health and Long-Term CareMcMaster UniversityUniversity of Calgary
KeywordsMedicineRandomized controlled trialEmpyemaChest tubePlaceboFibrinolytic agentSurgeryAdverse effectTissue plasminogen activatorClinical endpointClinical trialInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: A randomized controlled trial of adults with empyema recently demonstrated decreased length of stay in hospital in patients treated with intrapleurally administered dornase alfa and fibrinolytics compared to fibrinolytics alone. Whether this treatment strategy is safe and effective in children remains unknown. METHODS/DESIGN: This study protocol is for a superiority, placebo-controlled, parallel-design, multicenter randomized controlled trial. The participants are previously well children admitted to a children's hospital with a diagnosis of empyema requiring chest tube insertion and fibrinolytics administered intrapleurally. Children will be randomized after the treating physician has decided that pleural drainage is required but prior to chest tube insertion. After chest tube insertion, participants in the treatment group will receive intrapleurally administered tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5 mg. Participants in the placebo group will receive tPA 4 mg followed by normal saline. Study treatments will be administered once daily for 3 days. All participants, parents or caregivers, clinicians, and research personnel will remain blinded. The primary outcome is length of stay from chest tube insertion to discharge from hospital. Secondary outcomes include time to meeting discharge criteria, chest tube duration, fever duration, need for additional procedures, adverse events, hospital readmission, cost of hospitalization, and mortality. DISCUSSION: This multicenter randomized controlled trial will assess the safety, effectiveness, and cost-effectiveness of combined treatment with dornase alfa and fibrinolytics compared to fibrinolytics alone for the treatment of empyema in children. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01717742 . Registered on 8 October 2012.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.081
metaresearch head score (Gemma)0.078
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.081
Threshold uncertainty score0.430

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0810.078
Meta-epidemiology (narrow)0.0070.003
Meta-epidemiology (broad)0.0120.007
Bibliometrics0.0030.005
Science and technology studies0.0040.005
Scholarly communication0.0060.005
Open science0.0040.002
Research integrity0.0120.010
Insufficient payload (model declined to judge)0.0530.012

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.112
GPT teacher head0.439
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueTrialsSame topicPleural and Pulmonary DiseasesFrench-language works237,207